What is LOPJLB’s current signal on ELVN?

LOPJLB’s latest quantitative signal on Enliven Therapeutics, Inc. (ELVN) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is ELVN in?

Enliven Therapeutics, Inc. (ELVN) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does Enliven Therapeutics, Inc. (ELVN) do?

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, als…

Enliven Therapeutics, Inc. (ELVN)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$39.49-3.31%Close

SELLCRISIS · day 20

Company news

prnewswire.com · 8d ago

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

defenseworld.net · 8d ago

Enliven Therapeutics (NASDAQ:ELVN) Stock Falls 4.5% Following Insider Selling

benzinga.com · 12d ago

This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

seekingalpha.com · 27d ago

Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

prnewswire.com · 41d ago

Enliven Therapeutics to Present at Upcoming Investor Conferences

seekingalpha.com · 41d ago

Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing

prnewswire.com · 43d ago

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

defenseworld.net · 47d ago

BlackRock Inc. Invests $221.25 Million in Enliven Therapeutics, Inc. $ELVN

benzinga.com · 57d ago

Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

defenseworld.net · 69d ago

Dimensional Fund Advisors LP Raises Holdings in Enliven Therapeutics, Inc. $ELVN

prnewswire.com · 70d ago

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

defenseworld.net · 74d ago

Enliven Therapeutics, Inc. $ELVN is Avidity Partners Management LP’s 6th Largest Position

Market news & ticker search · RSS for ELVN

FAQ

What is LOPJLB’s current signal on ELVN?: LOPJLB’s latest quantitative signal on Enliven Therapeutics, Inc. (ELVN) is SELL in a CRISIS regime. Signals are updated daily.
What market regime is ELVN in?: Enliven Therapeutics, Inc. (ELVN) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does Enliven Therapeutics, Inc. (ELVN) do?: Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, als…

Enliven Therapeutics, Inc. (ELVN)

Key stats

Prediction markets

Company news

FAQ